贝伐珠单抗或贝伐珠单抗联合节拍化疗在FOLFOXIRI联合贝伐珠单抗一线诱导后维持治疗转移性结直肠癌患者的II期随机研究:MOMA试验
MOMA试验为II期随机研究,纳入不可切除转移性结直肠癌患者,接受最多8周期FOLFOXIRI联合贝伐珠单抗诱导后,随机分为贝伐珠单抗单药维持(A组)或贝伐珠单抗联合节拍化疗(卡培他滨500 mg每日三次+环磷酰胺50 mg/日,B组)直至疾病进展。主要终点无进展生存期未达到,B组与A组中位PFS分别为10.3个月与9.4个月(HR 0.94,70%CI 0.82-1.09,p=0.680),中位OS分别为22.5个月与28个月(HR 1.16,95%CI 0.99-1.37,p=0.336)。
要点
- 在贝伐珠单抗维持治疗中加入节拍化疗未显著改善无进展生存期(HR 0.94,p=0.680)。
- 中位总生存期B组22.5个月 vs A组28个月,无显著差异(HR 1.16,p=0.336)。
- FOLFOXIRI联合贝伐珠单抗诱导的缓解率为63%(B组58% vs A组68%)。
核心结论
- 在贝伐珠单抗维持治疗中加入节拍化疗未显著改善转移性结直肠癌患者的无进展生存期。
- FOLFOXIRI联合贝伐珠单抗4个月诱导方案在RAS/BRAF突变高 prevalence 人群中活性得到确认。
研究设计与样本
- II期随机研究,纳入不可切除转移性结直肠癌患者。
- 患者随机接受最多8周期FOLFOXIRI联合贝伐珠单抗诱导,随后分为贝伐珠单抗单药维持(A组)或贝伐珠单抗联合节拍化疗(卡培他滨500 mg每日三次+环磷酰胺50 mg/日,B组)直至疾病进展。
- 主要终点为无进展生存期;根据Rubinstein和Korn设计,为检测B组有利的HR 0.75,单侧α和β误差分别为15%和80%,需173个事件和222例患者。
- 2012年5月至2015年3月,共232例患者在16个意大利中心随机分组,多数为RAS突变(65%)或BRAF突变(9%)肿瘤。
主要发现
- 中位随访47.8个月,共登记210个进展事件和164个死亡事件。
- 主要终点未达到:B组与A组中位PFS分别为10.3个月与9.4个月(HR 0.94,70%CI 0.82-1.09,p=0.680)。
- 总生存期无显著差异:B组与A组中位OS分别为22.5个月与28个月(HR 1.16,95%CI 0.99-1.37,p=0.336)。
- FOLFOXIRI联合贝伐珠单抗的缓解率为63%(B组58% vs A组68%)。
- 在肝局限亚组中,二次切除率为49%(B组45% vs A组55%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alternating induction and maintenance phases is a common strategy in metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a well-tolerated chemotherapy backbone for maximising bevacizumab effect during maintenance. The MOMA trial was designed to compare metroCT plus bevacizumab versus bevacizumab alone as maintenance following 4 months of induction with FOLFOXIRI plus bevacizumab. PATIENTS AND METHODS: In this phase II study, patients with unresectable mCRC were randomised to receive up to 8 cycles of FOLFOXIRI plus bevacizumab, followed by bevacizumab (arm A) or the same regimen followed by bevacizumab plus metroCT (capecitabine 500 mg/three times per day and cyclophosphamide 50 mg/die, arm B) until disease progression. The primary end-point was progression-free survival (PFS). According to the Rubinstein and Korn's design, to detect a hazard ratio[HR] of 0.75 favouring arm B, with 1 sided-alpha and beta errors of 15% and 80%, 173 events and 222 patients were required. RESULTS: Between May 2012 and March 2015, 232 patients, mostly with RAS (65%) or BRAF (9%) mutant tumours, were randomised in 16 Italian centres. At a median follow-up of 47.8 months, 210 and 164 progression and death events were registered. The primary end-point was not met. Median PFS was 10.3 and 9.4 months in arm B and A, respectively (HR: 0.94 [70% confidence interval {CI}: 0.82-1.09], p = 0.680). No significant differences were reported in terms of overall survival (OS) (median OS arm B/A: 22.5/28 months; HR: 1.16 [95%CI: 0.99-1.37], p = 0.336). Response rate with FOLFOXIRI plus bevacizumab was 63% (arm B/A: 58%/68%). In the liver-limited subgroup, the secondary resection rate was 49% (arm B/A: 45%/55%). CONCLUSIONS: The addition of metroCT to maintenance with bevacizumab does not significantly improve PFS of mCRC patients. The activity of FOLFOXIRI plus bevacizumab is confirmed in a population with high prevalence of RAS/BRAF mutations treated with a 4-months induction. TRIAL REGISTRATION: www.clinicaltrials.gov NCT02271464.
引用
- Cremolini C, Marmorino F, Bergamo F, et al. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. Eur J Cancer. 2019. PMID: 30735919. doi:10.1016/j.ejca.2018.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。